A Clinical Study on the Safety and Efficacy of GCC Targeting CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
Latest Information Update: 24 May 2026
At a glance
- Drugs REVO UWD 01 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Wondercel Therapeutics
Most Recent Events
- 07 May 2026 Status changed from recruiting to suspended for the implementation of the new regulation policy by the Chinese authority.
- 20 May 2025 Status changed from not yet recruiting to recruiting.
- 10 Feb 2025 Planned initiation date changed from 10 Nov 2024 to 1 Jun 2025.